OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	113
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	58
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	53
Aflibercept biosimilars – so near, yet so far	52
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	44
Biosimilars and access to biologic therapy in immune-mediated diseases	44
Antibody drug conjugates for glioblastoma: current progress towards clinical use	40
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	39
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	38
The endosomal-lysosomal system in ADC design and cancer therapy	34
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	33
Correction	31
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	31
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	27
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	26
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	25
Signaling new therapeutic opportunities: cytokines in prostate cancer	24
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	24
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	21
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	21
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	21
Long-acting delivery and therapies for neovascular age-related macular degeneration	20
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	20
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	18
Correction	18

Moving toward personalized approaches in the management of lupus nephritis	17
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers	17
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	17
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	17
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	17
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	16
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	16
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	16
Unmet needs in cervical cancer – can biological therapies plug the gap?	16
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	15
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	15
Strategies for extending the half-life of biotherapeutics: successes and complications	15
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	15
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	14
Dynamics of biological markets with multiple biosimilar competitors in the United States	14
Management of proctitis in ulcerative colitis and the place of biological therapies	14
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	14
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	14
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	14
The nail in psoriatic arthritis: new insights into prognosis and treatment	14
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	14
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	14
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	14
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	13
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	13
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	13
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	13
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	13
Emerging peptide-based technology for biofilm control	13
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
Biological agents targeting interleukin-13 for atopic dermatitis	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	12
Recent advances in delivering RNA-based therapeutics to mitochondria	12
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	12
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	12
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	12
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?	12
Current status of developing tissue engineering vascular technologies	11
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	11
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	11
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	11
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	11
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	11
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	11
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	11
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	11
An evaluation of pozelimab for the treatment of CHAPLE disease	11

Personalizing immunotherapy for renal cell carcinoma: how far have we come?	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	10
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	10
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
Clinical management and innovation in fracture non-union	10
Treating psoriasis in the elderly: biologics and small molecules	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Biosimilars in osteoporosis treatment: focus on denosumab	10
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	10
Non-traditional approaches for control of antibiotic resistance	10
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Antibody therapeutics for epithelial ovarian cancer	10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	10
Correction	9
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
X-linked myotubular myopathy: an untreated treatable disease	9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	9
Prostate cancer immunotherapy	9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	9
Epcoritamab in B-cell malignancies: current status and prospects	9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	9
Sargramostim in acute radiation syndrome	9
Rilonacept for the treatment of recurrent pericarditis	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	8
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	8
Hemophilia A gene therapy: current and next-generation approaches	8
Ravulizumab for the treatment of myasthenia gravis	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy	8
Belantamab mafodotin in multiple myeloma	8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	8
Biologics in rectal cancer	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	8
CAR T cells for solid tumors – developments to watch in 2023	8
Non-TNF biologics and their biosimilars in rheumatoid arthritis	7
Rotavirus vaccines: progress and new developments	7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
The future of cancer vaccines against colorectal cancer	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
The future of interleukin gene therapy in head and neck cancers	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	7
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	7
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	7
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	7